Evommune reported net income of -$32.25M for the quarter ended Jun 2026. This income statement covers 8 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||
| Revenue | 3.00M | 10.00M | ||||||
| Operating items | ||||||||
| Research & DevelopmentR&D | 13.29M | 17.83M | 14.36M | 19.64M | 19.64M | 20.40M | 17.32M | 26.41M |
| Selling, General & AdministrativeSG&A | 3.23M | 3.62M | 3.67M | 3.36M | 3.69M | 9.31M | 6.63M | 8.48M |
| Operating ExpensesOpex | 16.52M | 21.45M | 18.03M | 22.99M | 23.33M | 29.72M | 23.95M | 34.90M |
| Operating IncomeOp. Inc | -16.52M | -21.45M | -15.03M | -22.99M | -13.33M | -29.72M | -23.95M | -34.90M |
| EBIT | -16.52M | -21.45M | -15.03M | -22.99M | -13.33M | -29.72M | -23.95M | -34.90M |
| Non-operating items | ||||||||
| Non Operating Interest Expenses | 0.02M | -0.00M | 0.01M | 0.03M | 0.01M | 0.00M | 0.00M | |
| Interest & Investment IncomeInt & Inv Inc | 0.62M | 0.73M | 0.61M | 0.40M | 0.86M | 1.44M | 2.28M | 2.65M |
| Other Non Operating IncomeOther Non Op Inc. | 0.60M | 0.73M | 0.47M | 9.43M | 0.85M | 1.44M | 2.28M | 2.65M |
| Net income details | ||||||||
| EBT | -15.92M | -20.73M | -14.43M | -22.62M | -12.47M | -28.27M | -21.67M | -32.25M |
| Profit After TaxPAT | -15.92M | -20.73M | -14.56M | -13.56M | -12.47M | -28.27M | -21.67M | -32.25M |
| Income from Continuing OperationsIncome (Continuing) | -15.92M | -20.73M | -14.43M | -22.62M | -12.47M | -28.27M | -21.67M | -32.25M |
| Consolidated Net IncomeConsol Net Inc. | -15.92M | -20.73M | -14.43M | -22.62M | -12.47M | -28.27M | -21.67M | -32.25M |
| Income towards Parent CompanyParent Net Inc | -15.92M | -20.73M | -14.43M | -22.62M | -12.47M | -28.27M | -21.67M | -32.25M |
| Net Income towards Common StockholdersNet Income | -15.92M | -20.73M | -14.43M | -22.62M | -12.47M | -28.27M | -21.67M | -32.25M |
| Additional items | ||||||||
| EPS (Basic) | -10.47 | -13.74 | -9.40 | -14.68 | -8.07 | -4.61 | -0.64 | -0.89 |
| EPS (Diluted) | -10.47 | -13.74 | -9.40 | -14.68 | -8.07 | -4.61 | -0.64 | -0.89 |
| Shares Outstanding | 1.52M | 1.51M | 1.53M | 1.54M | 1.55M | 6.14M | 33.67M | 36.14M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.52M | 1.51M | 1.53M | 1.54M | 1.55M | 6.14M | 33.67M | 36.14M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.55M | 1.55M | 1.55M | 1.55M | 1.55M | 6.14M | 36.02M | 36.28M |
| EBITDA | -16.52M | -21.45M | -15.03M | -22.99M | -13.33M | -29.72M | -23.95M | -34.90M |
| Interest ExpensesInt Expense | 0.02M | -0.00M | 0.01M | 0.03M | 0.01M | 0.00M | 0.00M |